Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
These days, the name Moderna (NASDAQ: MRNA) would make just about anyone think of the coronavirus vaccine. In only a year and a half, Moderna went from being a $6 billion biotech with no commercialized products or profit to a profitable, $184 billion vaccine powerhouse. Lives were saved...and fortunes were made. The stock has climbed more than 300% so far this year.
It's clear Moderna has been an excellent medium-term investment. But what about beyond that? Does Moderna have what it takes to make you richer if you hold onto the stock for the long term? Let's take a closer look at this innovative company and find out.
Image source: Getty Images.
Source Fool.com
